Levodopa (L-DOPA) structure · Parkinson

Levodopa (L-DOPA) 2D structure

Role: Drug
Family: Parkinson dopaminergic / MAO-B series
Mechanism class: Parkinson
Parent scaffold: Catecholamine / amino-acid core
Indication: Parkinson disease motor symptoms · FDA/EMA

Structure source: Catalog seed
FDA / EMA: FDA/EMA
ClinicalTrials.gov: levodopa Parkinson
Regulatory status: Approved · FDA/EMA · ClinicalTrials.gov · ClinicalTrials.gov

How similarity is calculated

Hand-written analysis

Mechanism

레보도파는 도파민의 혈액뇌장벽 통과 전구약물입니다. 말초 탈카르복실을 카르비도파가 막습니다. 장기 운동합병증(동요, 이상운동)이 핵심 과제입니다.

Medicinal chemistry

카테콜 아미노산입니다. 수용체 작용제·MAO-B 저해제와 층이 다릅니다.

Indication · context

파킨슨병의 운동 증상 표준입니다. 패밀리에서 보조 약과 경로를 나눕니다.

SMILES

N[C@@H](Cc1ccc(O)c(O)c1)C(=O)O

Related compounds

External IDs · BioMoa

PubChem 검색 ChEMBL 검색 PubChem (SMILES)BioMoa · CNS / Parkinson BioMoa bridge Open on the family map Flow Structure table CNS Deep Analysis Mechanism class

StructureMoa is a chemical-structure exploration tool. Structural similarity, clustering, and SAR relationships are intended for research exploration and do not establish shared potency, selectivity, safety, efficacy, or clinical performance.

Methodology

Levodopa (L-DOPA) structure · mechanism